Unknown PHASE1 INTERVENTIONAL 1-arm NCT03692520

Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors

Recombinant Anti-EGFR Monoclonal Antibody（SCT200）in Patients With Advanced Solid Tumors or Lymphoma : A Phase Ⅰb, Open-label, Multicenter Study.

Sponsor: Sinocelltech Ltd.

Conditions Advanced Solid Tumors

Interventions SCT200

Updated 5 times since 2018 Last updated: Sep 29, 2018 Started: Sep 30, 2018 Primary completion: Nov 30, 2019 Completion: Apr 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumors and is currently ongoing. Sinocelltech Ltd. leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jul 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Nov 2018 — Jul 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Sep 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinocelltech Ltd.

Data source: Sinocelltech Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China